Takuya Taguchi - Sumitomo Dainippon Sr Unit

Insider

Takuya Taguchi is Sr Unit of Sumitomo Dainippon Pharma
Phone81 6 6203 5321
Webhttps://www.sumitomo-pharma.com

Sumitomo Dainippon Management Efficiency

Sumitomo Dainippon's management efficiency ratios could be used to measure how well Sumitomo Dainippon manages its routine affairs as well as how well it operates its assets and liabilities.
Sumitomo Dainippon Pharma has accumulated 243.96 B in total debt with debt to equity ratio (D/E) of 0.36, which is about average as compared to similar companies. Sumitomo Dainippon Pharma has a current ratio of 1.71, which is within standard range for the sector. Debt can assist Sumitomo Dainippon until it has trouble settling it off, either with new capital or with free cash flow. So, Sumitomo Dainippon's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sumitomo Dainippon Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sumitomo to invest in growth at high rates of return. When we think about Sumitomo Dainippon's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Zorina PitkinOrganogenesis Holdings
N/A
Aaron PerlitshLifecore Biomedical
N/A
Sonny NewmanC21 Investments
N/A
Eric ShoemakerC21 Investments
N/A
Fredrik JarrstenOrexo AB
56
Luiz ClavisHypera SA
N/A
Brian GrowOrganogenesis Holdings
49
Ken GelhausAlpha Teknova
40
Dennis UrbaniakOrexo AB
54
Cecilia CouplandOrexo AB
47
Cindy PattonCumberland Pharmaceuticals
71
Damon TerrillAlpha Teknova
53
Patrick BilboOrganogenesis Holdings
63
Juliana SalemHypera SA
N/A
David FranciscoOrganogenesis Holdings
59
Kurt MathesonOrganogenesis Holdings
N/A
Matthew LowellAlpha Teknova
55
Robert RonnOrexo AB
47
Hlio SegourasHypera SA
N/A
BA EsqOrganogenesis Holdings
55
A MBACumberland Pharmaceuticals
67
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited. Dai Nippon operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 6987 people. Sumitomo Dainippon Pharma [DNPUF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Sumitomo Dainippon Pharma Leadership Team

Elected by the shareholders, the Sumitomo Dainippon's board of directors comprises two types of representatives: Sumitomo Dainippon inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sumitomo. The board's role is to monitor Sumitomo Dainippon's management team and ensure that shareholders' interests are well served. Sumitomo Dainippon's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sumitomo Dainippon's outside directors are responsible for providing unbiased perspectives on the board's policies.
Hisayoshi Kashima, Director of Accounting
Yoshiharu Ikeda, Executive Officer, Chief Director of Technology Research
Hiroyuki Baba, Executive Officer
Toru Kimura, Executive Officer, Manager of Regeneration & Cell Medicine Business Promotion Office
Takuya Taguchi, Sr Unit
Hiroshi Nomura, Director
Hideyuki Harada, Executive Officer, Chief Director of Research
Atsuko Higuchi, Executive Officer
Shigeyuki Nishinaka, Executive Officer, Director of Business Development
Naoki Noguchi, Corp Governance

Sumitomo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sumitomo Dainippon a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Consideration for investing in Sumitomo Pink Sheet

If you are still planning to invest in Sumitomo Dainippon Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sumitomo Dainippon's history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk